Product news from the 08/29/06 News Brief

Share this article:
The FDA yesterday approved several abbreviated new drug applications for generic versions of Bayer’s Cipro intravenous, a drug to treat certain bacterial infections.  Ciprofloxacin Injection, is now indicated for the treatment of infections, including urinary tract infections, lower respiratory tract infections (including pneumonias in hospitalized patients, nosocomial pneumonia), bone and joint infections, complicated intraabdominal infections, skin and skin structure infections, and therapy of patients with fever and neutropenia.   The FDA has approved the use of UCB’s Keppra (levetiracetam) as adjunctive therapy in the treatment of myoclonic seizures in adults and adolescents 12 years of age and older with juvenile myoclonic epilepsy. Keppra is widely prescribed as an add-on therapy in the treatment of partial onset seizures in adults and children four years of age and older with epilepsy.
Share this article:

Email Newsletters

More in Business Briefs

Miss Idaho shows off diabetes pump

NPR reports that the move has made Sierra Sandison a type 1 diabetes hero and that users have given the Facebook photo over 4,000 "likes."

Roche is hungry, not starving for M&A

CEO Severin Schwan tells Reuters that the Swiss firm will be looking for small acquisitions and partnerships.

AbbVie nabs Shire for $54B

AbbVie, in the latest example of a US drugmaker seeking to lower its tax rate, said today that it's buying Dublin-based Shire for $54 billion.